Jack W. Callicutt
2014
In 2014, Jack W. Callicutt earned a total compensation of $545.7K as Chief Financial Officer at Galectin Therapeutics, a 36% decrease compared to previous year.
Compensation breakdown
| Bonus | $38,500 |
|---|---|
| Option Awards | $293,402 |
| Salary | $175,000 |
| Other | $38,812 |
| Total | $545,714 |
Callicutt received $293.4K in option awards, accounting for 54% of the total pay in 2014.
Callicutt also received $38.5K in bonus, $175K in salary and $38.8K in other compensation.
Rankings
In 2014, Jack W. Callicutt's compensation ranked 9,986th out of 13,032 executives tracked by ExecPay. In other words, Callicutt earned more than 23.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,986 out of 13,032 | 23rd |
Division Manufacturing | 3,789 out of 4,966 | 24th |
Major group Chemicals And Allied Products | 1,303 out of 1,686 | 23rd |
Industry group Drugs | 1,042 out of 1,365 | 24th |
Industry Pharmaceutical Preparations | 800 out of 1,043 | 23rd |
Source: SEC filing on November 7, 2017.
Callicutt's colleagues
We found three more compensation records of executives who worked with Jack W. Callicutt at Galectin Therapeutics in 2014.
News
Galectin Therapeutics CEO Joel Lewis' 2023 pay slips 1% to $964K
December 3, 2024
Galectin Therapeutics CEO Joel Lewis' 2022 pay slips 17% to $974K
October 6, 2023
Galectin Therapeutics CEO Joel Lewis' 2021 pay jumps 55% to $1.2M
October 17, 2022
Galectin Therapeutics CEO Harold Shlevin's 2019 pay falls 25% to $1.3M
October 19, 2020